Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Enlivex Therapeutics Ltd. - Ordinary Shares (ENLV)
Company Research
Source: GlobeNewswire
Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for patent application number 2020800620493. Once issued, the resulting patent will provide Enlivex with added intellectual property protection in China through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. The Company expects that this new patent will be issued in China during the first half of 2025. Enlivex recently reported positive interim six (6) months efficacy data from the first stage
Read more
Impact Snapshot
Event Time:
ENLV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENLV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENLV alerts
High impacting Enlivex Therapeutics Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ENLV
News
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its price target raised by analysts at HC Wainwright from $6.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis [Yahoo! Finance]Yahoo! Finance
- Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee OsteoarthritisGlobeNewswire
- Enlivex Therapeutics Ltd. (NASDAQ: ENLV) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $13.00 price target on the stock.MarketBeat
- Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee OsteoarthritisGlobeNewswire
ENLV
Sec Filings
- 3/31/25 - Form 6-K
- 3/17/25 - Form 6-K
- 3/4/25 - Form 6-K
- ENLV's page on the SEC website